Endothelial function and its role in the formation of cardiovascular pathology in patients with rheumatoid arthritis

Abstract


Currently rheumatoid arthritis is considered as an immune inflammatory disease of unknown origin characterized by chronic erosive arthritis and systemic damage of internal organs, leading to early disability and reduced life expectancy. Cardiovascular diseases are most often mentioned as factors of poor prognosis in rheumatoid arthritis. Pathology of the cardiovascular system in rheumatoid arthritis is usually associated with the macro- and microvascular changes and rheumatoid lesions of the heart. The leading factor in the damage of the vascular wall in rheumatoid arthritis is systemic inflammation affecting its viscosity and elastic properties, increased rigidity, impaired endothelial function. Endothelial dysfunction is currently regarded to as an initial stage of morphogenesis of various vascular disorders. It is considered as a subclinical marker of cardiovascular diseases and the earliest predictor of cardiovascular complications. From this point of view study of endothelial dysfunction in patients with rheumatoid arthritis aimed at determining cardiovascular risk is a perspective direction. Only single and fragmentary information about certain endothelial functions in patients with rheumatoid arthritis and substances released in this. There is no clear analysis of relationship between them and dependence on the process activity. Not clear is their role in the pathology of the vascular wall in rheumatoid arthritis. This literature review discusses the problem of endothelial dysfunction in rheumatoid arthritis patients as well as its role in the development of cardiovascular diseases in these patients. The development mechanisms and the role of immune inflammation in its formation are considered. Also the association was found between chronic inflammatory activity indicators in rheumatoid arthritis and various biological markers and development of endothelial dysfunction. The effects of antirheumatic treatment on endothelial dysfunction in these patients were analyzed.


A A Tulichev

Privolzhsky Research Medical University

Author for correspondence.
Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

N Yu Borovkova

Privolzhsky Research Medical University

Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

N N Borovkov

Privolzhsky Research Medical University

Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

A A Spassky

Russian National Research Medical Univeersity n.a. N.I. Pirogov

Email: mr.tulichev@mail.ru
Moscow, Russia

I V Polyakova

Privolzhsky Research Medical University

Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

I Yu Maksimova

Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko

Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

S Yu Zubova

Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko

Email: mr.tulichev@mail.ru

Russian Federation, Nizhny Novgorod, Russia

  1. Nasonov E.L. Revmatologiya. Rossiyskiye klinicheskiye rekomendatsii. (Rheumatology. Russian clinical guidelines.) Moscow: GEOTAR-Med. 2019; 464 р. (In Russ.)
  2. Mavrogeni S., Dimitroulas T., Bucciarelli-Duccietal C. Rheumatoid arthritis: an autoimmune disease with female preponderance and cardiovascular risk equivalent to diabetes mellitus: role of cardiovascular magnetic resonance. Inflamm. Allergy Drug Targets. 2014; 13 (2): 81–93. doi: 10.2174/1871528113666140131151522.
  3. Krüger K., Nüßlein H. Cardiovascular comorbidi­ties in rheumatoid arthritis. Z. Rheumatol. 2019; 78 (3): ­221–227. doi: 10.1007/s00393-018-0584-5.
  4. Ntelios D., Karamitsos T.D., Boufidou A. et al. Inconsistent high sensitivity troponin T and I measurements in a patient with rheumatoid arthritis. Hellenic. J. Cardiol. 2018; 30: 1–2. pii: S1109-9666(18)30020-4. doi: 10.1016/j.hjc.2018.03.004.
  5. Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 52 (3): 722–732. doi: 10.1002/art.20878.
  6. Novikova D.S., Popkova T.V., Nasonov E.L. Current views on pathogenesis and the features of the treatment of arterial hypertension in rheumatoid arthritis. Terapevticheskiy arkhiv. 2011; (5): 24–33. (In Russ.)
  7. Popkova T.V., Novikova D.S., Nasonov E.L. Atherosclerosis in rheumatic diseases. In: Revmatologiya. Klinicheskie rekomendacii. (Rheumatology. Russian clinical guidelines.) Moscow: GEOTAR-Media. 2010; 678–702. (In Russ.)
  8. Balanescu S., Calmac L., Constantinescu D. et al. Systemic inflammation and early atheroma formation: are they related? Maedica (Buchar). 2010; 5 (4): 292–301. PMID: 21977173.
  9. Gunter S., Robinson C., Norton G.R. et al. Cardiovascular risk factors and disease characteristics are consistently associated with arterial function in rheumatoid arthritis. J. Rheumatol. 2017; 44 (8): 1125–1133. doi: 10.3899/jrheum.170029.
  10. Bordy R., Totoson P., Prati C. et al. Microvascular endothelial dysfunction in rheumatoid arthritis. Nat. Rev. Rheumatol. 2018; 5 (8): 125–129. doi: 10.1038/s41584-018-0022-8.
  11. Knyazeva L.I., Me­shcherina N.S., Knyazeva L.A. et al. Proinflammatory mediators and endothelial dysfinction in rheumatoid arthritis. Uspekhi sovremennogo estestvoznaniya. 2015; (2): 63–67. (In Russ.)
  12. Kade A.Kh., Zanin S.A., Gubareva Ye.A. et al. Physiological functions of vascular endothelium. Fundamental'nyye issledovaniya. 2011; (11-3): 611–617. (In Russ.)
  13. Volkov A.V., Mach E.S., Guseva N.G. Endothe­lial dysfunction in systemic sclerosis — clinical and pathogenetic correlation. Terapevticheskiy arkhiv. 2008; (10): ­68–72. (In Russ.)
  14. Jamnitski A., Symmons D., Peters M.J. et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann. Rheum. Dis. 2013; 72 (2): 211–216. doi: 10.1136/annrheumdis-2011-201194.
  15. Adawi M., Watad A., Bragazzi N.L. et al. Endothelial function in rheumatoid arthritis. QJM. 2018; 111 (4): 243–247. doi: 10.1093/qjmed/hcy010.
  16. Von Hundelshausen P., Weber C. Chronic inflammation and atherosclerosis. Dtsch. Med. Wochenschr. 2013; 138 (37): 1839–1844. doi: 10.1055/s-0033-1349426.
  17. Caraba A., Crişan V., Romoşan I. et al. Vitamin D status, disease activity, and endothelial dysfunction in early rheumatoid arthritis patients. Dis. Markers. 2017; 2017: 5241012. doi: 10.1155/2017/5241012.
  18. Marder W., Khalatbari S., Myles J.D. et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann. Rheum. Dis. 2011; 70 (9): 1550–1555. doi: 10.1136/ard.2010.148031.
  19. Shilkina N.P., Butusova S.V., Dryazhenkova I.V. System of microcirculation, markers of vascular wall damage and systematicity of the process in rheuma­tic diseases. Angiologiya i Sosudistaya Khirurgiya. 2014; 20 (1): 27–34. (In Russ.)
  20. Dessein P.H., Solomon A., Woodiwiss A.J. Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis. Mediators Inflamm. 2013; 2013: 510243. doi: 10.1155/2013/510243.
  21. Erre G.L., Piga M., Fedele A.L. et al. Prevalence and determinants of peripheral microvascular endothelial dysfunction in rheumatoid arthritis patients: A multicenter cross-sectional study. Mediators Inflamm. 2018; 6: 548–715. doi: 10.1155/2018/6548715.
  22. Adawi M., Watad A., Bragazzi N.L. et al. Endothelial function in rheumatoid arthritis. QJM. 2018; 111 (4): 243–247. doi: 10.1093/qjmed/hcy010.
  23. Grunina E.A., Gal'perin E.V., Yudovich E.A. Comparison of endothe­lial function in patients with rheumatoid arthritis and ische­mic heart disease. Nizhegorodskiy meditsinskiy zhurnal. 2005; (4): 111–113. (In Russ.)
  24. Foster W., Carruthers D., Lip G.Y. et al. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J. Rheumatol. 2010; 37 (4): 711–716. doi: 10.3899/jrheum.090699.
  25. Dimitroulas T., Hodson J., Sandoo A. et al. Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. Arthritis Res. Ther. 2017; 19 (1): 32. doi: 10.1186/s13075-017-1232-1.
  26. Garg N., Syngle A., Krishan P. et al. Nitric oxide: Link between inflammation and endothelial dysfunction in rheumatoid arthritis. Int. J. Angiol. 2017; 26 (3): 165–169. doi: 10.1055/s-0036-1597577.
  27. Moroni L., Selmi C., Angelini C. et al. Evaluation of endothelial function by flow-mediated dilation: a comprehensive review in rheumatic disease. Arch. Immunol. Ther. Exp. (Warsz.). 2017; 65 (6): 463–475. doi: 10.1007/s00005-017-0465-7.
  28. Kang J.H., Keller J.J., Lin Y.K. et al. A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J. Vasc. Surg. 2012; 56 (6): 1642–1648. doi: 10.1016/j.jvs.2012.05.087.
  29. Skeoch S., Bruce I.N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat. Rev. Rheumatol. 2015; 11 (7): 390–400. doi: 10.1038/nrrheum.2015.
  30. Mahmoudi M., Aslani S., Fadaei R. et al. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int. J. Rheum. Dis. 2017; 20 (3): ­287–297. doi: 10.1111/1756-185X.12999.
  31. Khanna N.N., Jamthikar A.D., Gupta D. et al. Rheumatoid arthritis: Atherosclerosis imaging and cardiovascular risk assessment using machine and deep learning-based tissue characterization. Curr. Atheroscler. Rep. 2019; 21 (2): 7. doi: 10.1007/s11883-019-0766-x.
  32. Urman A., Taklalsingh N., Sorrento C. Inflammation beyond the joints: Rheumatoid arthritis and cardiovascular disease. Scifed. J. Cardiol. 2018; 2 (3). pii: 1000019. PMID: 30607397.
  33. Deyab G., Hokstad I., Whist J.E. et al. ­Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. ­Arthritis Res. Ther. 2017; 19 (1): 232. doi: 10.1186/s13075-017-1439-1.
  34. Rongen G.A., van Ingen I., Kok M. et al. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin. Rheumatol. 2018; 37 (4): ­909–916. doi: 10.1007/s10067-017-3961-6.
  35. Ursini F., Leporini C., Bene F. Anti-TNF-­alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci. Rep. 2017; 7 (1): 5346. doi: 10.1038/s41598-017-05759-2.
  36. Kotani K., Miyamoto M., Ando H.et al. The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis. Curr. Vasc. Pharmacol. 2017; 15 (1): 10–18. doi: 10.2174/1570161114666161013113457.
  37. Spinelli F.R., Metere A., Barbati C. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators Inflamm. 2013; 2013: 537–539. doi: 10.1155/2013/537539.
  38. Verhoeven F., Totoson P., Maguin-Gaté K. et al. Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis. Clin. Exp. Immunol. 2017; 188 (2): 208–218. doi: 10.1111/cei.12938.
  39. Verhoeven F., Totoson P., Marie C. et al. Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis. Athe­rosclerosis. 2017; 266: 136–144. doi: 10.1016/j.atherosclerosis.2017.09.033.
  40. Komarova E.B., Rebrov B.A., Knyazeva A.K. An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis. Sovremennaya revmatologiya. 2017; 11 (3): 72–76. (In Russ.)
  41. Sluyter J.D., Hughes A.D., Lowe A. et al Different associations between beta-blockers and other antihypertensive medication combinations with brachial blood pressure and aortic waveform parameters. Int. J. Cardiol. 2016; 219: 257. doi: 10.1016/j.ijcard.2016.06.051.
  42. Yao R., Cheng X., Liao Y.H. et al. Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesteroldietapolipoprotein E-knockout mice. J. Cardiovasc. Pharmacol. 2008; 2: 188–195. doi: 10.1097/FJC.0b013e31815f2bce.
  43. McCarey D.W., McInnes I.B., Madhok R. et al. ­Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double­blind, randomized placebo-controlled trial. Lancet. 2004; 363: 2015–2021. doi: 10.1016/S0140-6736(04)16449-0.

Views

Abstract - 40

PDF (Russian) - 51

PlumX


© 2019 Tulichev A.A., Borovkova N.Y., Borovkov N.N., Spassky A.A., Polyakova I.V., Maksimova I.Y., Zubova S.Y.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Свидетельство о регистрации СМИ ЭЛ № ФС 77-75008 от 1 февраля 2019 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)